Aura Biosciences gets FDA fast track status for belzupacap sarotalocan
Aura Biosciences has secured fast track designation for belzupacap sarotalocan (AU-011) from the US Food and Drug Administration (FDA) for the treatment of non-muscle invasive ... Read More
Aura Biosciences raises $80m for VDC therapies for cancers
Aura Biosciences, a portfolio company of UK-based Arix Bioscience, has raised $80 million in a new funding round for developing virus-like drug conjugate (VDC) therapies ... Read More